Yüklüyor......
LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
BACKGROUND: Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat associated with significant mortality and medical cost. Microbiota therapy is gaining acceptance as a strategy to reduce rCDI recurrence. We present the final 24-month analysis of clinical safety, effic...
Kaydedildi:
| Yayımlandı: | Open Forum Infect Dis |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6810069/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz415.2488 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|